heading · body

YouTube

Outer Space: The Next Economic Frontier | WSJ

WSJ Events published 2026-05-29 added 2026-06-04 score 7/10
space space-economy biotech manufacturing infrastructure low-earth-orbit startups
watch on youtube → view transcript

ELI5 / TLDR

A space architect named Ariel Ekla argues that the interesting money in space is not Mars — it is the thin layer of orbit a couple hundred miles above our heads. Two things changed: shipping cargo to orbit got roughly 30x cheaper in 15 years, and 20 years of biology experiments showed that some things (delicate tissues, drug crystals) come out better when nothing is sagging under gravity. Her company is building “space Legos” — flat tiles with magnets on the edges that float together into ball-shaped structures, so you can build things in orbit far bigger than any rocket can carry. The pitch to a business audience: space is no longer a niche sector, it is a place to manufacture and operate, and the first real businesses there will be biolabs, solar arrays, and maybe data centers.

The Full Story

The pitch: space is closer than California

Ekla opens with a reframe. To a room in New York, the International Space Station is about 250 miles up — closer than the West Coast. The point is not trivia. She wants the audience to stop filing “space” under exotic moonshots and start treating low Earth orbit as an emerging market that is physically near and commercially live.

Space is no longer a sector that may or may not be relevant for your business. Space is a domain. It’s a physical emerging market.

She deliberately turns away from the Mars conversation that SpaceX and the recent Artemis 2 moon mission dominate. Her bet is on the near neighborhood: build useful infrastructure right above Earth first, and let that pay for the grander stuff later.

Why we still build space stations by hand

Here is the problem she is solving. Everything in orbit today is, in her words, an aluminum tin can — pressurized cylinders shaped to fit inside a rocket’s nose cone (the “payload fairing,” the protective tube at the rocket’s tip). The International Space Station was bolted together piece by piece by astronauts in spacesuits doing spacewalks. Impressive, but it does not scale on cost, speed, or safety.

Her PhD work at MIT borrowed a trick from nature: self-assembly. DNA folds itself; ants link their bodies into bridges across gaps too wide for one ant. The logic for the final shape is baked into each part. So she designed tiles — “space Legos” — with powerful magnets on their edges. In orbit there is no friction and no weight pulling them down, so the magnets quietly tug the tiles together with no engines required. Think of how a MacBook charger snaps onto the laptop and seats itself — that, scaled up, is the whole mechanism.

The tiles pack flat (she compares them to Pringles or a Pez dispenser), get popped out of a rocket one at a time, and assemble into a “bucky ball” — a soccer-ball shape that approximates a sphere. Why a sphere? Because the expensive part of anything in space is the outer shell that holds the air in, and for a given amount of shell, a sphere holds the most volume inside. A true sphere is hard to pack and build, so a faceted soccer-ball is the practical stand-in.

They have tested this for real — first on “vomit comet” flights (a plane that arcs steeply to give 20-30 seconds of weightlessness at the top, how NASA trains astronauts), then on suborbital rockets, then palm-sized versions actually self-assembling inside the ISS.

The business layer

Ekla runs a two-part outfit: Aurelia Institute (a nonprofit doing far-future research) and Aurelia Foundry (a venture fund that spins out the bits that make commercial sense). The first spinout is Rendezvous Robotics, and notably it is not chasing human habitats first. Keeping humans breathing in space is hard. So Rendezvous targets easier “beachhead” markets that still need giant self-assembled structures: huge orbital solar arrays (sunlight is stronger above the clouds), big antennas for national security, and possibly AI data centers in orbit. Her logic: if you want to build something three or four football fields wide, you cannot fold it into a rocket like origami — you have to assemble it up there.

Two tailwinds: cheaper launch, microgravity biology

The economic case rests on one number. Getting a kilogram of cargo to orbit cost about $50,000 fifteen years ago. Today it is around $1,500. With SpaceX’s Starship, the projection is under $200.

If you can ship cargo around the world, you can ship it to space.

At those prices, launching hundreds of thousands of tiles to build orbital infrastructure stops being absurd.

The second tailwind is biology. Twenty years of ISS experiments showed that some biological processes simply work better in freefall. Three examples she highlights:

  • Artificial retinas — these are built in ~200 ultra-thin stacked layers. On Earth the layers sag under gravity; floating, they don’t, giving a manufacturing-quality jump. A partner company hopes to win FDA approval to restore sight lost to macular degeneration.
  • Organoids — tiny lab-grown clumps of cells that stand in for real organs so scientists can test drugs without using actual organs. They grow with better 3D shape and mature faster in zero-g, making them better targets for testing cancer and Alzheimer’s drugs.
  • Keytruda (she pronounces it “Kruda”) — Merck’s ~$30 billion-a-year cancer drug. Merck took an early formulation to orbit to study how the protein crystallizes, and that data helped convert it from an IV drip you get in a hospital to an outpatient shot. The key nuance: space was used for data, not manufacturing. You don’t have to make every dose in orbit — you just need the insight.

Her near-term product is an orbital biolab. The ISS is scheduled for decommissioning around 2030-2031 (NASA will carefully empty it and let it burn up in the atmosphere). NASA is repeating the SpaceX playbook — having handed off transport to private companies, it now wants commercial firms to run the space stations while NASA pushes further out to the Moon and Europa. Roughly six companies are competing to replace the ISS. Aurelia’s angle is to contribute a self-assembled biotech module, staffed eventually not just by career astronauts but by “citizen scientists” who rotate through on tours, the way people work two-weeks-on shifts at an Arctic research station or on an oil rig.

The big-picture closers

Ekla ends with two ideas. First, space lets you build things impossible on Earth — she shows an 1800s design for a 150-meter Newton memorial dome that was unbuildable then because no one could span an arch that wide. Without gravity, monumental architecture becomes feasible.

Second, and the line she clearly cares most about: space as a tool for Earth, not an escape from it. The science-fiction idea she invokes is “off-worlding” — moving not people but dirty heavy industry (mining, polluting chemical manufacturing) off the planet. In a vacuum there is no atmosphere or biosphere trapping the byproducts the way Earth does. Her candidate first mover: AI data centers, an energy-hungry new industry that hasn’t been fully built out on Earth yet, so maybe it should be born in orbit instead.

Space exploration is not about abandoning Earth… we can also use space technologies as a lever to help Earth and maybe eventually let Earth recover as a garden planet.

Key Takeaways

  • Launch cost to orbit fell from ~$50,000/kg (15 years ago) to ~$1,500/kg today, with Starship projected under $200/kg — the single number that makes orbital construction economically plausible.
  • “Space Legos”: flat, magnet-edged tiles that self-assemble in orbit using no propulsion, because freefall removes friction and weight. They form a faceted “bucky ball” sphere to maximize interior volume per unit of expensive outer shell.
  • The first commercial markets aren’t human habitats (life support is too hard) — they’re giant solar arrays, antennas, and possibly AI data centers, plus orbital biolabs.
  • Microgravity improves certain biology: layered tissues (retinas) don’t sag, and organoids grow with better 3D structure and mature faster — better for drug testing.
  • Keytruda case study: Merck used orbit only for crystallization data, then reformulated an IV drug into an outpatient shot on the ground. Space’s value can be information, not manufacturing.
  • The ISS is set for decommissioning (burn-up) around 2030-2031; NASA is handing low-Earth-orbit stations to ~6 competing private operators while it pushes toward the Moon and Europa.
  • “Off-worlding”: the proposal to relocate polluting heavy industry to the vacuum of space, where there’s no biosphere to trap byproducts — framed as using space to let Earth recover.

Claude’s Take

This is a polished VC-and-recruiting pitch dressed as a talk, and you should read it that way. The technical core — magnetic self-assembly of tiles, tested on the ISS — is real and genuinely clever, and the launch-cost numbers are accurate and the most important fact in the whole space economy right now. The biology examples are the strongest part: the Keytruda reformulation actually happened, and the “use space for data, not mass manufacturing” insight is the kind of unglamorous economics that separates a real business from a fantasy.

Where to keep your guard up: the timeline hand-waves. “Your kids will commute to space for work” and “AI data centers in orbit” are the parts where the deck gets ahead of the physics — orbital data centers have brutal unsolved problems (cooling in vacuum, radiation, servicing) that she waves toward as a “debate off the stage.” The $200/kg Starship figure is a projection, not a reality. And the “off-worlding heavy industry” close is more vibe than plan; mining asteroids or running chemical plants in orbit is decades and many trillions away, if ever.

Scored a 7: substantive, honest about being early-stage, and the cheap-launch plus microgravity-biology thesis is a legitimately useful mental model. Docked points because it’s a single-speaker promotional talk with no pushback, and the most exciting claims are the least supported. Good for understanding why people are pouring money into low Earth orbit; not a substitute for skepticism about the splashier projections.

Further Reading

  • Keytruda (pembrolizumab) — Merck’s PD-1 immunotherapy; look up the microgravity protein-crystallization work behind its subcutaneous reformulation.
  • Buckminster Fuller — the “bucky ball” geodesic geometry is named after him; the engineering logic of spheres and geodesic domes.
  • Étienne-Louis Boullée, Cenotaph for Newton (1784) — the unbuildable 150-meter memorial dome she cites as architecture awaiting a gravity-free site.
  • Anthropocene — the framing she riffs on with her “anthropocosmos” coinage; humanity as a dominant geological force.